In vitro and in vivo investigations on the antiviral activity of a series of mixed-valence rare earth borotungstate heteropoly blues.
A series of mixed-valence rare earth borotungsto-heteropoly blues, K15H2[Ln(BW9W2O39)2].28H2O (Ln2, Ln=La, Ce, Pr, Nd, Sm, Eu, Gd), have been prepared and characterized by IR, UV, XPS, ESR and electrochemistry. The cytotoxicity and antiviral activity of these rare earth borotungstate heteropoly blues were investigated against influenza A(FluVA) strain (A/H1N1/Jingfang/1/91 and A/H3N2/Jingfang/30/95) and influenza virus B(FluVB) (B/Hufang/1/87) in MDCK cells. The results show that K15H2[Pr(BW9W2O39)2].28H2O (Pr2) exhibits the highest antiviral activity against FluVA with EC50 of less than 4.0 microg/ml (A/H1N1/Jingfang/1/91) and 6.0 microg/ml (A/H3N2/Jingfang/30/95), respectively, and has the lowest toxicity with CC50 of more than 480 microg/ml against MDCK cells. Additionally, both K15H2[Pr(BW9W2O39)2].28H2O (Pr2) and K15H2[Eu(BW9W2O39)2].28H2O (Eu2) showed excellent antiviral activities against FluVB by inhibiting FluVB replication at an EC50 of less than 8.0 microg/ml. Furthermore, investigation on in vivo antiviral activity of Pr2 against FluVA(FM1) in mice by giving the dosage either orally (p.o.) or intraperitoneally (i.p.), indicates that Pr2 exhibits higher inhibitory activity than that of positive control, virazole, and that it's more effective when administered by i.p.
Liu
Ya-Nan
YN
Department of Chemistry, Jinan University, Guangzhou 510632, PR China.
Shi
Shuo
S
Mei
Wen-Jie
WJ
Tan
Cai-Ping
CP
Chen
Lan-Mei
LM
Liu
Jie
J
Zheng
Wen-Jie
WJ
Ji
Liang-Nian
LN
D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D001835:Body Weight / Q000187:drug effects; D001896:Boron Compounds / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D002460:Cell Line; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004563:Electrochemistry; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000502:physiology; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects / Q000502:physiology; D009981:Influenza B virus / Q000187:drug effects / Q000502:physiology; D008674:Metals, Rare Earth / Q000737:chemistry*; D051379:Mice; D013057:Spectrum Analysis; D015996:Survival Rate; D017973:Tungsten Compounds / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity
D000998:Antiviral Agents; D001896:Boron Compounds; D008674:Metals, Rare Earth; D017973:Tungsten Compounds; C067364:borotungstic acid